Safety of intravenous push thiamine administration at a tertiary academic medical center
This 2020 retrospective study evaluated 8,606 intravenous (IV) push thiamine administrations in 2,595 adult patients at a tertiary academic medical center. Doses ranged from 100 mg to 500 mg, with the majority administered peripherally. The study found no instances of anaphylaxis or anaphylactoid reactions. Injection site reactions were rare, occurring
June 26, 2025
No Comments